Pharmacyclics Revenue, Profits - PCYC Annual Income Statement

Add to My Stocks
$261.25 $0 (0%) PCYC stock closing price May 26, 2015 (Closing)

Fundamental analysis of PCYC stock involves analyzing its financial statements, apart from checking the Pharmacyclics stock price. In the income statement, an investor can look at important parameters like revenue or sales, gross profits, net profits, and EPS basic to gain deeper insights. The income statement is always for an accounting period, typically for a year or quarter, and affects the stock. In this case, the PCYC stock is bound to reflect the impact of the YOY growth of 180.49%. Along with Pharmacyclics assets and Pharmacyclics free cash flow, Pharmacyclics profits as shown in profit and loss statement give key insights about the business. The net profit for 2014 is $86.12M and the 2014 revenue is $729.72M.

View revenue and profit details for latest and last 10 financial years.
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec2014201320122011201020092008
Pharmacyclics Revenues or Net Sales
729.72M260.16M57.96M77.9M2.82M4.7M-
Cost Of Goods Sold (COGS)40.41M3.5M-----
Pharmacyclics Gross Profit
689.31M256.66M57.96M77.9M2.82M4.7M-
Research & Development Expense172.45M85.13M10.26M12.07M8.25M3.72M2.98M
Selling General & Admin Expense393.95M73.61M6.4M3.94M2.09M1.76M1.87M
Income Before Depreciation Depletion Amortization122.9M97.92M41.29M61.88M-7.52M-0.78M-4.86M
Depreciation Depletion Amortization-------
Non Operating Income-------
Interest Expense-------
Pharmacyclics Pretax Income
122.44M98.13M41.37M61.9M-7.49M-0.76M-4.83M
Provision for Income Taxes36.32M31.12M-0.55M5.65M--0.55M-
MinorityInterest-------
Investment Gains Losses-------
Other Income-------
Income Before Extraordinaries & Disc Operations86.12M67.01M41.92M56.25M-7.49M-0.21M-4.83M
Extraordinary Items & Discontinued Operations-------
Pharmacyclics Profit/ Loss (Net Income)
86.12M67.01M41.92M56.25M-7.49M-0.21M-4.83M
Average Shares used to compute Diluted EPS78.15M77.08M72.62M59.97M48.34M26.57M25.99M
Average Shares used to compute Basic EPS75.25M72.78M68.73M59.97M48.34M26.57M25.99M
Income Before Nonrecurring Items85.6M67.01M11.99M-35.79M-16.76M-23.45M-24.3M
Income from Nonrecurring Items----1.74M--
Pharmacyclics Earnings Per Share Basic Net
1.140.920.17-0.59-0.31-0.88-0.93
Pharmacyclics Earnings Per Share Diluted Net
1.100.870.17-0.59-0.31-0.88-0.93
EPS Diluted Before Nonrecurring Items1.090.870.17-0.60-0.35-0.88-0.93
Preferred Dividends Acc Pd-------
Dividends Common-------
Dividend Per Share Common0.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Pharmacyclics stock analysis involves checking at least a few of the important things like:

  • Topline: A growing topline, as seen from the Pharmacyclics revenue chart, as is the case with Pharmacyclics indicates a growing business. One needs to compare the YoY topline or sales growth of PCYC stock with its peers like ESALY stock and FRX stock to see if the growth compares well with what can be expected from a company in that industry.
  • Bottom line: The bottomline or the net income figure is arrived at by deducting all expenses from the topline which in this case is $86.12M for PCYC stock. An improving bottomline implies that the company is growing its profits.

The income statement is also called the profit and loss statement. Apart from the PCYC income statement, one can check the Pharmacyclics historical stock prices to check how the price has moved with time.